Tag Archives: epidermal growth-factor receptor

Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Currently, no treatment exists for lung cancer patients with epidermal growth-factor receptor (EGFR) mutation who have failed tyrosine kinase inhibitors, getifinib (Iressa) or erlotinib (Tarceva).  However, an investigational drug, afatinib (BIBW 2992), was recently found to increase progression-free survival and … Continue reading

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , , , | Comments Off on Afatinib Extend Time to Tumor Progression in Advanced Lung Cancer

Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations

Gefitinib (Iressa) is more effective than first-line therapy in improving survival without disease in patients with advanced nonsmall-cell lung cancer (NSCLC) and epidermal growth-factor receptor (EGFR) mutations.  The current study was conducted in 230 patients from 43 centers in Japan, … Continue reading

Posted in Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , | Comments Off on Gefitinib (Iressa) is better than Standard Therapy in Lung Cancer with EGFR Mutations